Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity

Kimberly A. Hanson, James W. Ziegler, Sergei D. Rybalkin, Jim W. Miller, Steven H. Abman, William R. Clarke

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

An experimental ovine fetal model for perinatal pulmonary hypertension of the neonate (PPHN) was characterized by altered pulmonary vasoreactivity and structure. Because past studies had suggested impaired nitric oxide-cGMP cascade in this experimental model, we hypothesized that elevated phosphodiesterase (PDE) activity may contribute to altered vascular reactivity and structure in experimental PPHN. Therefore, we studied the effects of the PDE inhibitors zaprinast and dipyridamole on fetal pulmonary vascular resistance and PDE5 activity, protein, mRNA, and localization in normal and pulmonary hypertensive fetal lambs. Infusion of dipyridamole and zaprinast lowered pulmonary vascular resistance by 55 and 35%, respectively, in hypertensive animals. In comparison with control animals, lung cGMP PDE activity was elevated in hypertensive fetal lambs (150%). Increased PDE5 activity was not associated with either an increased PDE5 protein or mRNA level. Immunocytochemistry demonstrated that PDE5 was localized to vascular smooth muscle. We concluded that PDE5 activity was increased in experimental PPHN, possibly by posttranslational phosphorylation. We speculated that these increases in cGMP PDE activity contributed to altered pulmonary vasoreactivity in experimental perinatal pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)L931-L941
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume275
Issue number5 19-5
StatePublished - Dec 7 1998

Fingerprint

Phosphoric Diester Hydrolases
Pulmonary Hypertension
Lung
Dipyridamole
Vascular Resistance
Messenger RNA
Phosphodiesterase Inhibitors
Vascular Smooth Muscle
Blood Vessels
Sheep
Nitric Oxide
Proteins
Theoretical Models
Immunohistochemistry
Phosphorylation
zaprinast

Keywords

  • Dipyridamole
  • Guanosine 3',5'-cyclic monophosphate
  • Persistent pulmonary hypertension of the newborn
  • Vasoregulation

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

Hanson, K. A., Ziegler, J. W., Rybalkin, S. D., Miller, J. W., Abman, S. H., & Clarke, W. R. (1998). Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 275(5 19-5), L931-L941.

Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. / Hanson, Kimberly A.; Ziegler, James W.; Rybalkin, Sergei D.; Miller, Jim W.; Abman, Steven H.; Clarke, William R.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 275, No. 5 19-5, 07.12.1998, p. L931-L941.

Research output: Contribution to journalArticle

Hanson, KA, Ziegler, JW, Rybalkin, SD, Miller, JW, Abman, SH & Clarke, WR 1998, 'Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 275, no. 5 19-5, pp. L931-L941.
Hanson, Kimberly A. ; Ziegler, James W. ; Rybalkin, Sergei D. ; Miller, Jim W. ; Abman, Steven H. ; Clarke, William R. / Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 1998 ; Vol. 275, No. 5 19-5. pp. L931-L941.
@article{7b62d3d675c84a039cbf5398f575843c,
title = "Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity",
abstract = "An experimental ovine fetal model for perinatal pulmonary hypertension of the neonate (PPHN) was characterized by altered pulmonary vasoreactivity and structure. Because past studies had suggested impaired nitric oxide-cGMP cascade in this experimental model, we hypothesized that elevated phosphodiesterase (PDE) activity may contribute to altered vascular reactivity and structure in experimental PPHN. Therefore, we studied the effects of the PDE inhibitors zaprinast and dipyridamole on fetal pulmonary vascular resistance and PDE5 activity, protein, mRNA, and localization in normal and pulmonary hypertensive fetal lambs. Infusion of dipyridamole and zaprinast lowered pulmonary vascular resistance by 55 and 35{\%}, respectively, in hypertensive animals. In comparison with control animals, lung cGMP PDE activity was elevated in hypertensive fetal lambs (150{\%}). Increased PDE5 activity was not associated with either an increased PDE5 protein or mRNA level. Immunocytochemistry demonstrated that PDE5 was localized to vascular smooth muscle. We concluded that PDE5 activity was increased in experimental PPHN, possibly by posttranslational phosphorylation. We speculated that these increases in cGMP PDE activity contributed to altered pulmonary vasoreactivity in experimental perinatal pulmonary hypertension.",
keywords = "Dipyridamole, Guanosine 3',5'-cyclic monophosphate, Persistent pulmonary hypertension of the newborn, Vasoregulation",
author = "Hanson, {Kimberly A.} and Ziegler, {James W.} and Rybalkin, {Sergei D.} and Miller, {Jim W.} and Abman, {Steven H.} and Clarke, {William R.}",
year = "1998",
month = "12",
day = "7",
language = "English (US)",
volume = "275",
pages = "L931--L941",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "5 19-5",

}

TY - JOUR

T1 - Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity

AU - Hanson, Kimberly A.

AU - Ziegler, James W.

AU - Rybalkin, Sergei D.

AU - Miller, Jim W.

AU - Abman, Steven H.

AU - Clarke, William R.

PY - 1998/12/7

Y1 - 1998/12/7

N2 - An experimental ovine fetal model for perinatal pulmonary hypertension of the neonate (PPHN) was characterized by altered pulmonary vasoreactivity and structure. Because past studies had suggested impaired nitric oxide-cGMP cascade in this experimental model, we hypothesized that elevated phosphodiesterase (PDE) activity may contribute to altered vascular reactivity and structure in experimental PPHN. Therefore, we studied the effects of the PDE inhibitors zaprinast and dipyridamole on fetal pulmonary vascular resistance and PDE5 activity, protein, mRNA, and localization in normal and pulmonary hypertensive fetal lambs. Infusion of dipyridamole and zaprinast lowered pulmonary vascular resistance by 55 and 35%, respectively, in hypertensive animals. In comparison with control animals, lung cGMP PDE activity was elevated in hypertensive fetal lambs (150%). Increased PDE5 activity was not associated with either an increased PDE5 protein or mRNA level. Immunocytochemistry demonstrated that PDE5 was localized to vascular smooth muscle. We concluded that PDE5 activity was increased in experimental PPHN, possibly by posttranslational phosphorylation. We speculated that these increases in cGMP PDE activity contributed to altered pulmonary vasoreactivity in experimental perinatal pulmonary hypertension.

AB - An experimental ovine fetal model for perinatal pulmonary hypertension of the neonate (PPHN) was characterized by altered pulmonary vasoreactivity and structure. Because past studies had suggested impaired nitric oxide-cGMP cascade in this experimental model, we hypothesized that elevated phosphodiesterase (PDE) activity may contribute to altered vascular reactivity and structure in experimental PPHN. Therefore, we studied the effects of the PDE inhibitors zaprinast and dipyridamole on fetal pulmonary vascular resistance and PDE5 activity, protein, mRNA, and localization in normal and pulmonary hypertensive fetal lambs. Infusion of dipyridamole and zaprinast lowered pulmonary vascular resistance by 55 and 35%, respectively, in hypertensive animals. In comparison with control animals, lung cGMP PDE activity was elevated in hypertensive fetal lambs (150%). Increased PDE5 activity was not associated with either an increased PDE5 protein or mRNA level. Immunocytochemistry demonstrated that PDE5 was localized to vascular smooth muscle. We concluded that PDE5 activity was increased in experimental PPHN, possibly by posttranslational phosphorylation. We speculated that these increases in cGMP PDE activity contributed to altered pulmonary vasoreactivity in experimental perinatal pulmonary hypertension.

KW - Dipyridamole

KW - Guanosine 3',5'-cyclic monophosphate

KW - Persistent pulmonary hypertension of the newborn

KW - Vasoregulation

UR - http://www.scopus.com/inward/record.url?scp=0031767180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031767180&partnerID=8YFLogxK

M3 - Article

C2 - 9815111

AN - SCOPUS:0031767180

VL - 275

SP - L931-L941

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 5 19-5

ER -